All In Biotech

NDA 220860 · Takeda Pharms USA

Orzeyful

Oveporexton · Oral

NovelPriority reviewOrphan

CDER novel approval, Aug 5, 2026: To treat narcolepsy type 1

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Aug 5, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

2 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2026.

ORZEYFUL TM is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients. ORZEYFUL is an orexin receptor 2 (OX2R) agonist indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients. ( 1 )

Mechanism: The mechanism of action of oveporexton in the treatment of narcolepsy type 1 (NT1) is through agonism of the orexin receptor 2 (OX2R). NT1 is associated with the loss of orexin neuropeptide signaling.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 5, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
3 products under this application
  • ORZEYFUL · OVEPOREXTON 2MG · TABLET, ORAL · Prescription
  • ORZEYFUL · OVEPOREXTON .05MG · TABLET, ORAL · Prescription
  • ORZEYFUL · OVEPOREXTON 1MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oveporexton" as an intervention, any sponsor and status, largest first.

All 2 trials
  • TakedaTakeda (TAK)

    NCT06470828 · 168 participants · Start Jul 2, 2024 · Primary completion Jun 3, 2025

    Drug: Oveporexton; Placebo · For: Narcolepsy Type 1

    Sites: Phoenix, Arizona; Redwood City, California; Santa Ana, California · 53 sites in all

  • TakedaTakeda (TAK)

    NCT06505031 · 105 participants · Start Oct 8, 2024 · Primary completion Jun 4, 2025

    Drug: TAK-861; Placebo · For: Narcolepsy Type 1

    Sites: Glebe, Australia; Linz, Austria; Alken, Belgium · 28 sites in all

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.